JP2021523938A5 - - Google Patents

Info

Publication number
JP2021523938A5
JP2021523938A5 JP2021510564A JP2021510564A JP2021523938A5 JP 2021523938 A5 JP2021523938 A5 JP 2021523938A5 JP 2021510564 A JP2021510564 A JP 2021510564A JP 2021510564 A JP2021510564 A JP 2021510564A JP 2021523938 A5 JP2021523938 A5 JP 2021523938A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
mixture
pharmaceutically acceptable
neurosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523938A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000517 external-priority patent/WO2019211668A2/en
Publication of JP2021523938A publication Critical patent/JP2021523938A/ja
Publication of JP2021523938A5 publication Critical patent/JP2021523938A5/ja
Pending legal-status Critical Current

Links

JP2021510564A 2018-05-04 2019-05-03 神経ステロイド誘導体およびその使用 Pending JP2021523938A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862667100P 2018-05-04 2018-05-04
US62/667,100 2018-05-04
US16/403,100 2019-05-03
PCT/IB2019/000517 WO2019211668A2 (en) 2018-05-04 2019-05-03 Neurosteroid derivatives and uses thereof
US16/403,100 US20190337975A1 (en) 2018-05-04 2019-05-03 Neurosteroid derivatives and uses thereof

Publications (2)

Publication Number Publication Date
JP2021523938A JP2021523938A (ja) 2021-09-09
JP2021523938A5 true JP2021523938A5 (enExample) 2022-05-02

Family

ID=68384780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510564A Pending JP2021523938A (ja) 2018-05-04 2019-05-03 神経ステロイド誘導体およびその使用

Country Status (11)

Country Link
US (2) US20190337975A1 (enExample)
EP (1) EP3788055A4 (enExample)
JP (1) JP2021523938A (enExample)
CN (1) CN112823164A (enExample)
AR (1) AR116659A1 (enExample)
AU (1) AU2019264032A1 (enExample)
CA (1) CA3099089A1 (enExample)
PY (1) PY1934080A (enExample)
TW (1) TW202014192A (enExample)
UY (1) UY38213A (enExample)
WO (1) WO2019211668A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
AU2014308621C1 (en) 2013-08-23 2022-01-06 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN117024501A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
IL295362A (en) * 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids
IL295902A (en) * 2020-02-27 2022-10-01 Brii Biosciences Inc Drug inhibitors of neuroactive steroids
EP4493574A1 (en) * 2022-03-18 2025-01-22 Marinus Pharmaceuticals, Inc. Prodrugs of ganaxolone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB748846A (en) * 1953-10-28 1956-05-09 Vitamins Ltd A process for the manufacture of pregnan-3(-a)-ol-20-one and derivatives thereof
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
ES2296594T3 (es) * 1994-02-14 2008-05-01 Euro-Celtique S.A. Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
WO2006010085A1 (en) * 2004-07-09 2006-01-26 Roxro Pharma, Inc. Use of neurosteroids to treat neuropathic pain
US20130245253A1 (en) * 2010-03-26 2013-09-19 Department Of Veterans Affairs Conjugated Neuroactive Steroid Compositions And Methods Of Use
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
WO2015081170A2 (en) * 2013-11-26 2015-06-04 Systamedic Inc. Ganaxolone derivatives for treatment of central nervous systems disorders
CA3068462A1 (en) * 2017-06-23 2019-12-27 The Board Of Trustees Of The University Of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
CN109666055A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 调节中枢神经治疗抑郁症的化合物及其用途

Similar Documents

Publication Publication Date Title
JP2021523938A5 (enExample)
JP6951506B2 (ja) 皮膚の炎症を処置するためのpufaの使用
BE1013477A3 (fr) Formulation.
JP2021523938A (ja) 神経ステロイド誘導体およびその使用
ES2261570T3 (es) Medicamento basado en gestagenos para aplicacion por via dermica que contiene acido ascorbico asi como sales del mismo.
ES2253423T3 (es) Formulacion de un ester de testosterona para uso humano.
RU2690659C2 (ru) Композиции для местного применения, содержащие кортикостероид
CA2869676A1 (en) Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
KR20200052934A (ko) 경피 제제
JPS6341887B2 (enExample)
JP2022517724A (ja) テストステロンの活性エステル誘導体、組成物、およびそれらの使用
JPS60172925A (ja) 胆石溶解剤
JP2005533036A (ja) 油性溶液の自己投与型避妊注射
MC2150A1 (fr) Utilisation de derives d'acides alkylphophoriques pour la lutte contre les maladies du type psoriasis
US3541209A (en) Method of alleviating hypertrophic conditions
ITMI20121205A1 (it) Composizione con attivita' antinfiammatoria ed analgesica da somministrare per uso esterno mediante vaporizzazione
US20160074320A1 (en) Pharmaceutical compostions comprising kisspeptin or derivatives thereof
JP7134329B2 (ja) ウンデカン酸テストステロンを含む安定した薬学的組成物
EP3607959A1 (en) Formulations containing lipophilic extracts of spicy edible plants useful in controlling pain and inflammation
JP6786252B2 (ja) 皮膚用の医薬組成物
CA3187883A1 (en) Topical composition
HK40021662A (en) Use of pufas for treating skin inflammation
JPH083073A (ja) 経皮吸収促進剤及び皮膚外用剤
SA01210722B1 (ar) تكوين صيدلي يحتوي على فولفسترانت fulvestrant
PL214858B1 (pl) Środek leczniczy na bazie noretysteronu lub jego farmaceutycznie dopuszczalnej pochodnej i estradiolu lub jego farmaceutycznie dopuszczalnej pochodnej